Global Acute Agitation and Aggression Treatment Market Size (2024 - 2029)

The acute agitation and aggression treatment market is projected to experience growth over the forecast period, driven by factors such as an increasing geriatric population and heightened awareness of agitation and aggression. The COVID-19 pandemic has significantly influenced the market by affecting drug production and demand, disrupting distribution channels, and increasing the need for treatments due to rising aggression in the population. Continuous product innovation and research into novel treatments are also contributing to market expansion. However, the market's growth may be hindered by a preference for non-pharmacological interventions and the social stigma surrounding mental illness.

Market Size of Global Acute Agitation and Aggression Treatment Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
acute agitation and aggression treatment
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 4.90 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Global Acute Agitation and Aggression Treatment Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Acute Agitation & Aggression Treatment Market Analysis

The acute agitation and aggression treatment market is expected to register a CAGR of 4.9% during the forecast period.

The COVID-19 pandemic has impacted the market significantly. The COVID-19 pandemic had few major effects on the global market for acute agitation and aggression treatment market. The pandemic has directly affected the production and demand of agitation and aggression drugs. It has disrupted distribution channels and had a financial impact on firms and financial markets. However, the clinical trials have increased, and numerous studies have been conducted to find the impact of COVID-19 on agitation and aggression. For instance, according to the article 'Predictors of Adolescent Resilience During the COVID-19 Pandemic: Cognitive Reappraisal and Humor' published in November 2021, more anxiety, depressive symptoms, sleep disturbances, and proactive aggression were linked to greater COVID-19 impact. This suggests that due to increasing aggression among the target population, the demand for psychotic drugs or other treatments for the management of agitation and aggression increased during the pandemic. Therefore, owing to the mentioned factors, the COVID -19 pandemic has significantly impacted the studied market.

Factors such as a rise in the geriatric population and an increase in agitation in patients, an increase in focus on creating awareness about agitation and aggression, and ongoing research on the development of novel treatments for agitation are expected to fuel the market growth over the forecast period.

The increase in the geriatric population is expected to be a major contributor to the studied market. According to World Health Organization (WHO) data published in October 2021, between 2015 and 2050, the proportion of the world's population over 60 years is predicted to nearly double from 12% to 22%. In 2050, 80% of older people will be living in low- and middle-income countries. This target population is more prone to getting age-related agitation and anger issues. Additionally, this population accounts for dementia, which triggers aggression among them. Thus, the increase in the number of geriatrics demands for the availability of treatment options. Thereby driving the demand for the market studied.

Moreover, continuous product innovation and developments are major contributors to market growth. For instance, in May 2022, the first patient was dosed in the TRANQUILITY II study of acute treatment for agitation in patients with Alzheimer's disease. The TRANQUILITY II study is led by BioXcel Therapeutics and focuses on BXCL501, an orally dissolving thin film formulation of dexmedetomidine. Thus, the developments in the market are anticipated to boost market growth over the analysis period.

Therefore, due to the factors mentioned above, the studied market is anticipated to witness growth during the forecast period. However, the preference for non-pharmacological interventions and social stigma associated with mental illness is predicted to restrain the growth of the market.

Acute Agitation & Aggression Treatment Industry Segmentation

As per the scope of the report, Agitation is generally defined as excessive verbal and/or motor behavior. It can escalate to aggression, which can be either verbal (vicious cursing and threats) or physical (toward objects or people). The Acute Agitation and Aggression Treatment Market is segmented by Route of Administration (Oral, Intramuscular and Others), Drug Class (Anti-psychotics, Benzodiazepines and Others), End Users (Hospitals & Ambulatory Surgical Centers, Psychiatric Care Facilities and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Route of Administration
Oral
Intramuscular
Others
By Drug Class
Anti-psychotics
Benzodiazepines
Others
By End Users
Hospitals & Ambulatory Surgical Centers
Psychiatric Care Facilities
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Acute Agitation and Aggression Treatment Market Size Summary

The acute agitation and aggression treatment market is poised for growth, driven by several key factors. The increasing geriatric population, particularly those prone to age-related agitation and dementia, is a significant contributor to market expansion. The COVID-19 pandemic has also played a pivotal role, impacting drug production and demand while disrupting distribution channels. However, it has spurred clinical research, highlighting the need for effective treatments. Continuous product innovation, such as the development of novel treatments and the approval of new drugs like IGALMI, further propels market growth. Despite these advancements, challenges such as the preference for non-pharmacological interventions and the social stigma surrounding mental illness may hinder market progress.

North America emerges as a dominant region in the acute agitation and aggression treatment market, largely due to its substantial geriatric population and ongoing development activities. The region's market growth is supported by a rise in clinical trials and the introduction of new therapies, such as INP105 for autism spectrum disorder. The market is characterized by fragmentation, with numerous players like Eli Lilly and Company, Pfizer, Inc., and H. Lundbeck A/S focusing on product development and innovation. These companies are actively involved in clinical trials and regulatory approvals, contributing to the competitive landscape and driving the market forward.

Explore More

Global Acute Agitation and Aggression Treatment Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rise in Geriatric Population and Increase in Agitation in Patients

      2. 1.2.2 Increase in Focus on Creating Awareness About Agitation and Aggression

      3. 1.2.3 Ongoing Research on the Development of Novel Treatment for Agitation

    3. 1.3 Market Restraints

      1. 1.3.1 Preference for Non-Pharmacological Interventions

      2. 1.3.2 Social Stigma Associated With Mental Illness

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Route of Administration

      1. 2.1.1 Oral

      2. 2.1.2 Intramuscular

      3. 2.1.3 Others

    2. 2.2 By Drug Class

      1. 2.2.1 Anti-psychotics

      2. 2.2.2 Benzodiazepines

      3. 2.2.3 Others

    3. 2.3 By End Users

      1. 2.3.1 Hospitals & Ambulatory Surgical Centers

      2. 2.3.2 Psychiatric Care Facilities

      3. 2.3.3 Others

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle-East and Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of Middle-East and Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

Global Acute Agitation and Aggression Treatment Market Size FAQs

The Global Acute Agitation and Aggression Treatment Market is projected to register a CAGR of 4.90% during the forecast period (2024-2029)

Eli Lilly and Company, H. Lundbeck A/S, GSK plc, Otsuka Pharmaceutical Co., Ltd. and Pfizer, Inc. are the major companies operating in the Global Acute Agitation and Aggression Treatment Market.

Acute Agitation and Aggression Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)